Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis [Cut&Run ChIP-seq]

ABSTRACT: Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis [Cut&Run ChIP-seq]

PROVIDER: PRJNA604071 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis [Cut&Run ChIP-seq]

Project description:Several different YAP1 gene fusions have been identified in various human cancers. We performed Cut and Run Chip sequencing on human neural stem cells overexpressing either YAP1-MAMLD1, YAP1-FAM118B, YAP1-TFE3, wild type YAP1, wild type MAMLD1, wild type FAM118B, wild type TFE3, or S127/397A-YAP1 (all HA tagged at the N'terminus)

2020-08-04 | GSE144581 | GEO

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis[RNASeq]

Project description:Several different YAP1 gene fusions have been identified in various human cancers. We performed RNA sequencing on human neural stem cells overexpressing either YAP1-MAMLD1, YAP1-FAM118B, or YAP1-TFE3, as well as on whole tumor lysates from mouse brain tumors generated by intra-cranial expression of either YAP1-MAMLD1, YAP1-FAM118B, or YAP1-TFE3.

2020-08-04 | GSE137038 | GEO

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis [mouse RNA-seq]

2020-08-04 | GSE137039 | GEO

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis

Project description:Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis

| PRJNA564312 | ENA

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis[RNASeq]

Project description:Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis[RNASeq]

| PRJNA564315 | ENA

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis [mouse RNA-seq]

Project description:Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis [mouse RNA-seq]

| PRJNA564316 | ENA

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis.

Project description: Not available

| S-EPMC7397849 | biostudies-literature

Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.

Project description: Not available

| S-EPMC6715383 | biostudies-literature

CUT&RUN Profiling in CBF-Glis2 AMLs Identifies the Chromatin Remodeler Brg1 as a Key Dependency

Project description:Oncogenic fusions involving transcription factors are present in the majority of pediatric leukemias, however, the context-specific mechanisms they employ to drive cancer remain poorly understood. CBFA2T3-GLIS2 (C/G) fusions occur in treatment-refractory acute myeloid leukemias and are restricted to young children. To understand how the C/G fusion drives oncogenesis we applied CUT&RUN chromatin profiling to an umbilical cord blood/endothelial cell (EC) co-culture model of C/G AML that recapitulates the biology of this malignancy. We find C/G fusion binding is mediated by its zinc finger domains. Integration of fusion binding sites in C/G-transduced cells with PRC2 sites in control cord blood cells identifies MYCN, WT1, and GATA2 as C/G targets. Transcriptomic analysis of a pediatric AML cohort shows that these genes are upregulated in C/G patient samples. Single cell RNA-sequencing of umbilical cord blood identifies a population of megakaryocyte precursors that already express many of these genes despite lacking the fusion. By integrating CUT&RUN data with CRISPR dependency screens we identify BRG1/SMARCA4 as a vulnerability in C/G AML. Brg1 profiling in C/G patient-derived cell lines shows that the CBFA2T3 promoter is a binding site, and treatment with clinically-available Brg1 inhibitors reduces fusion levels and downstream C/G targets including N-Myc, killing C/G leukemia cells.

2023-08-07 | GSE239849 | GEO

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-08-04 | GSE137040 | GEO